


## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number  
**WO 01/13783 A1**

- (51) International Patent Classification<sup>7</sup>: **A61B 5/00**
- (21) International Application Number: **PCT/EP00/08285**
- (22) International Filing Date: **24 August 2000 (24.08.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
60/150,792 26 August 1999 (26.08.1999) **US**  
60/185,980 1 March 2000 (01.03.2000) **US**
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).**
- (74) Agent: **BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- (71) Applicant (for AT only): **NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59 A-1230 Vienna (AT).**
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **MARCH, Wayne, Front [US/US]; 2946 Dominique, Galveston, TX 77551 (US).**
- Published:**  
— With international search report.  
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **OCULAR ANALYTE SENSOR**

(57) Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.

WO 01/13783 A1

WO 01/13783

- 1 -

PCT/EP00/08285

Ocular Analyte Sensor

An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid which is accessible to light. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body that is not as accessible, such as blood or intracellular fluid.

Various noninvasive or minimally invasive methods to measure analytes, particularly glucose, have been described. For example, March, U.S. Patents 3,958,560 and 4,014,321, discloses a glucose sensor wherein a patient's eye is automatically scanned using a source of light at one side of the cornea. A sensor located at the other side of the cornea detects the light that passes through the cornea. The level of glucose which rotates the plan of polarized light in the aqueous humor of the patient is a function of the amount of radiation detected. However, this sensor system is not necessarily specific or widely applicable to detection of analytes other than glucose, because it does not exploit the use of biological molecules which can detect glucose or other analytes in a body tissue or fluid sample. Biological molecules, as is well known, can provide very specific and sensitive detection reagents for particular analytes.

Schultz, U.S. Patent 4,344,438, discloses a system for monitoring low molecular weight compounds in blood plasma by optical means, which involves a chamber which contains specific receptor sites for the plasma constituent to be analyzed. This system is very invasive, however, because it must be implanted within the blood stream using a hypodermic needle. The system also inherently contains the risks of clotting around the device, obstruction, and other adverse reactions, including immune reactions, general irritation, and foreign body reactions.

Embodiments of the present invention overcome these disadvantages in the prior art by employing an ophthalmic lens comprising a receptor moiety which comprises an

WO 01/13783

PCT/EP00/08285

- 2 -

analyte/competitor moiety binding site to detect an analyte in an ocular fluid. Concentration of a wide variety of analytes can be measured using an ophthalmic lens according to embodiments of the invention. Such analytes include, but are not limited to, electrolytes and small molecules (*e.g.*, sodium, potassium, chloride, phenylalanine, uric acid, galactose, glucose, cysteine, homocysteine, calcium, ethanol, acetylcholine and acetylcholine analogs, ornithine, blood urea nitrogen, creatinine), metallic elements (*e.g.*, iron, copper, magnesium), polypeptide hormones (*e.g.*, thyroid stimulating hormone, growth hormone, insulin, luteinizing hormones, chorionogonadotrophic hormone), chronically administered medications (*e.g.*, dilantin, phenobarbital, propranolol), acutely administered medications (*e.g.*, cocaine, heroin, ketamine), small molecule hormones (*e.g.*, thyroid hormones, ACTH, estrogen, cortisol, estrogen, and other metabolic steroids), markers of inflammation and/or allergy (*e.g.*, histamine, IgE, cytokines), lipids (*e.g.*, cholesterol), plasma proteins and enzymes (*e.g.*, complement, coagulation factors, liver function enzymes, heart damage enzymes, ferritin), markers of infection (*e.g.*, virus components, immunoglobulins such as IgM, IgG, etc., proteases, protease inhibitors), and/or metabolites (*e.g.*, lactate, ketone bodies).

Ophthalmic lenses according to embodiments of the invention can be used to monitor the course of therapy or the level of disease in mammals, including primates and, preferably, humans. In addition, because ophthalmic lenses according to embodiments of the invention provide a way to detect analytes noninvasively, they provide distinct advantages over more traditional forms of monitoring such levels. Ophthalmic lenses according to embodiments of the invention also are useful for diagnostic purposes, for example to test for pregnancy (to detect  $\beta$ -HCG), to assess blood chemistry (electrolytes,  $\text{Ca}_2\text{PO}_4$ , magnesium, bilirubin, alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase, etc.), and to detect infection (*e.g.*, by detecting components of viruses such as CMV, EBV, hepatitis, and HIV, or bacteria, such as *Staphylococcus*, *Streptococcus*, etc.). They also are useful for monitoring blood levels of test compounds during the course of assessing the compounds for use as potential therapeutics.

Ophthalmic lenses according to embodiments of the invention can be worn chronically to provide repeated analyte measurements or can be worn for a single analyte measurement. Both qualitative and quantitative measurements can be performed.

WO 01/13783

PCT/EP00/08285

- 3 -

### Ophthalmic Lens

An ophthalmic lens according to embodiments of the invention can be a removable lens, such as a contact lens, or a permanently implanted lens, such as an intraocular lens, a subconjunctival lens, or an intracorneal lens. See US Serial Nos. 60/150,792 and 60/185,980, the patent applications the priority of which is claimed for this invention. Permanently implanted lenses are particularly well-suited for use in individuals who have compromised ocular function (*e.g.*, cataracts) and also have chronic conditions which require analyte measurement, such as diabetics.

Ophthalmic lenses can be corrective lenses or can be constructed so that they do not affect visual acuity. Contact lenses optionally can comprise a tint and are preferably disposable, which reduces the risk of infection for the user. As used herein, the term "ophthalmic lens" may also refer to a shunt or implant that may rest in the cul de sac of the eye.

### Receptor Moiety

The ophthalmic lens comprises a receptor moiety. The receptor moiety comprises a binding site for the analyte to be detected. The binding site also binds a moiety which competes with the analyte for binding and is therefore referred to herein as an "analyte/competitor moiety binding site." Binding of both the competitor moiety and the analyte to the analyte/-competitor moiety binding site is reversible. The nature of the molecule used as the receptor moiety depends on the particular analyte to be detected, but minimally includes that portion of the molecule which is sufficient to contain an analyte/competitor moiety binding site.

For example, if glucose is the analyte to be detected, the receptor moiety preferably is concanavalin A (Mansouri & Schultz, *Bio/Tech* 2, 385, 1984), although other moieties, such as antibodies, boronic acid, a genetically engineered bacterial fluoroprotein, or glucose oxidase also can be used. If phenylalanine is the analyte to be detected, the receptor moiety preferably comprises the active site of phenylalanine hydroxylase. It is well within the skill of those knowledgeable in the art to determine other analyte-receptor moiety binding pairs, such as uric acid-uricase, alcohol-alcohol dehydrogenase, copper-ceruloplasmin, galactose-galactokinase, cysteine- and/or homocysteine-cystathionine synthetase, acetylcholine-acetylcholinesterase, ornithine-diamine oxidase, and the like.

### Competitor Moiety

WO 01/13783

PCT/EP00/08285

- 4 -

For use in detecting an analyte, an ophthalmic lens according to embodiments of the invention preferably comprises a competitor moiety having a detectable label. The competitor moiety competes with the analyte for binding to the analyte/competitor moiety binding site. The detectable label can intrinsically be part of the competitor moiety. Alternatively, the detectable label can be a label which is not naturally associated with the competitor moiety but which is attached by means of a chemical linkage, such as a covalent bond. In preferred embodiments, the competitor moiety comprises a fluorescent label. Other detectable labels, such as luminescent or colorimetric labels, also can be used.

Again, it is well within the skill of those in the art to select a competitor moiety which will compete with an analyte for binding to a particular analyte/competitor moiety binding site. For example, competitor moieties which can be used with the analyte-receptor moiety binding pairs disclosed above include fluorescein dextran (which competes with glucose for binding to concanavalin A), fluorescein polyglutamylurate (which competes with uric acid for binding to uricase), fluorescein nanolol (which competes with alcohol for binding to alcohol dehydrogenase), fluorescein-glutamine phenylacetate (which competes with phenylalanine for binding to phenylalanine hydroxylase), fluorescein-erythrocytorein (which competes with copper for binding to ceruloplasmin), fluorescein- 2,3,6-tri-O-methyl galactose (which competes with galactose for binding to galactokinase), fluorescein-S-adenosyl polyhomocysteine (which competes with cysteine and homocysteine for binding to cystathionine synthetase), fluoropolyglutamyl prostigmine (which competes with acetylcholine for binding to acetylcholinesterase), and fluorospermine (which competes with ornithine for binding to diamine oxidase).

Most preferably, the detectable label is more readily detectable when the competitor moiety is not bound to the analyte/competitor moiety binding site. Thus, fluorescent labels, such as fluorescein, indocyanine green, malachite green, and rhodamine, which are quenched when the competitor moiety is bound but are unquenched when the competitor moiety is not bound, are preferred for use in ophthalmic lenses according to embodiments of the invention.

*Providing Receptor and Competitor Moieties in an Ophthalmic Lens*

WO 01/13783

PCT/EP00/08285

- 5 -

A variety of options are available for providing the receptor and competitor moieties in an ophthalmic lens. Construction of various types of ophthalmic lenses is well known in the art. Construction of contact lenses is taught, for example, in U.S. Patents 5,965,631, 5,894,002, 5,849,811, 5,807,944, 5,776,381, 5,426,158, 4,099,859, 4,229,273, 4,168,112, 4,217,038, 4,409,258, 4,388,164, 4,332,922, 4,143,949, 4,311,573, 4,589,964, and 3,925,178.

Construction of intraocular lens implants is taught, *inter alia*, in U.S. Patents 6,051,025, 5,868,697, 5,762,836, 5,609,640, 5,071,432, 5,041,133, and 5,007,928. Subconjunctival lenses are taught, for example, in U.S. Patents 5,476,511, 5,400,114, and 5,127,901. Intracorneal lenses are taught, *inter alia*, in U.S. Patents 6,090,141, 5,984,961, 5,123,921, and 4,799,931.

In one embodiment, the receptor moiety is covalently bound to the ophthalmic lens material. In another embodiment, the ophthalmic lens comprises a polymer meshwork containing pores. The pores are of a size which permit the competitor moiety to bind reversibly to the analyte/competitor moiety binding site, but which prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens. Suitable polymers for this purpose are known in the art and include hydrogels, such as stable polymers of polyethylene glycol hydrogel (PEGH) (March *et al.*, 2000), and modified polyvinylalcohol, such as nelfilcon A.

In another embodiment, the ophthalmic lens comprises a receptor moiety layer, a polyelectrolyte layer, and a competitor moiety layer. The polyelectrolyte layer includes one or more polyelectrolytes, which are generally high molecular weight polymers with multiple ionic or ionizable functional groups. At least one polyelectrolyte in the polyelectrolyte layer has a charge opposite to the overall charge of the receptor moiety and competitor moiety layers. Suitable polyelectrolytes include positively charged PDDA (polydiallyldimethylammonium chloride) and negatively charged PAA (polyacrylic acid). Assembly of the layers is based upon sequential adsorption of oppositely charged polyions. The sensor and spacing polyelectrolytes are deposited as uniform thin films (1-10 nm) in 10-15 deposition cycles onto the porous polyvinyl alcohol or hydrogen matrix, resulting in only a 100-500 nm thick coating for the sensing film, which is highly biocompatible. A typical sequence for construction of an ophthalmic lens suitable for glucose detection involves a deposition cycle of ultrathin (1-10 nm) films of PDDA, PAA, PDDA, concanavalin A, PDDA, PAA, PDDA,

WO 01/13783

PCT/EP00/08285

- 6 -

fluorescein dextran, PDDA, PAA, PDDA, PAA, concanavalin A, PAA, fluorescein dextran, PAA, etc. Technology for constructing ophthalmic lenses comprising such layers is taught, for example, in WO 99/35520.

An ophthalmic lens according to embodiments of the invention can be provided in a kit, together with instructions for measuring analyte concentration as described below. The invention provides kits which are intended for individual patient use, in which the ophthalmic lens typically is a contact lens, as well as kits for medical practitioners, which can comprise any of the ophthalmic lenses or their equivalents described herein.

#### Analyte Sensor System

An ophthalmic lens according to embodiments of the invention can be used in an analyte sensor system. The analyte sensor system comprises an ophthalmic lens and a detector configured to detect the detectable label. For example, if the label is a luminescent label, the detector may include a luminometer; if the label is a colorimetric label, the detector may include a colorimeter; if the label is a fluorescent label, the detector may include a fluorophotometer. Construction of such devices is well known in the art. Light with wavelengths which will excite the fluorescent label can be provided, for example, by a laser or a light source, such as a light-emitting diode. A fluorophotometer suitable for use with embodiments of the invention can be constructed using a light-emitting diode from Power Technology, Inc. (Little Rock, AR) (see March *et al.*, *Diabetes Technol. & Ther.* 2, 27-30, 2000).

The detector can be a free-standing device, a table-top device, or a hand-held device. For convenience, the detector can be a miniaturized device and may be worn or carried as a personal accessory, for example, mounted in the frame of a pair of eyeglasses, clipped to an article of clothing, such as a shirt or sweater, hung around the neck, worn around the wrist, or clipped to a belt or a key ring.

Using an ophthalmic lens in an analyte sensor system, as described above, embodiments of the invention provides methods of measuring analyte concentration in an ocular fluid. This measurement can, in turn, be manipulated to provide a measurement of the analyte's concentration in a body tissue or a fluid, such as blood or intracellular fluid. The relationship between glucose concentration in the aqueous humor and the blood, for example, is well known. See Süllmann, in HANDBUCH DER PHYSIOLOGISCHEN CHEMIE, Vol. II/a, p. 867 ff.,

WO 01/13783

PCT/EP00/08285

- 7 -

Springer, Berlin, 1956; Graymore, in *THE EYE*, Vol. I, p. 348, Davson, ed., Academic Press, NY, 1962; De Berardinis *et al.*, *Exp. Eye Res.* 4, 179, 1965; Pohjola, *Acta Ophthalmologica Suppl.* 88, 1966; Reim *et al.*, *Ophthalmologica* 154, 39-50, 1967; Kinsey & Reddy, in Prince, ed., *THE RABBIT AND EYE RESEARCH*, C.C. Thomas, Springfield, IL, 1964, p. 218. The relationship between the concentration of another analyte in a body tissue or fluid and the concentration of the analyte in an ocular fluid can be determined by methods well known in the art. See, for example, March *et al.*, *Diabetes Care* 5, 259-65, 1982. The detector can be configured to convert the measurement of the analyte concentration into a value which reflects the concentration of the analyte in the relevant body tissue or fluid, *e.g.*, blood.

If desired, the analyte sensor system also can comprise a transmitter configured to transmit a signal representing whether the detectable label is detected and/or an amount of the detectable label that is detected. A device configured to vary the concentration of the analyte in a body fluid or tissue, such as an infusion pump or other pump, may receive the signal and may vary the concentration response to the signal. The signal from the analyte sensor system may comprise a continuous or discontinuous telemetry signal generated by the detector. The pump may, in response to the signal, adjust the levels of the analyte in the body by providing the user with the appropriate amount of a regulator moiety, such as insulin. Infusion pumps are well known in the art for delivering a selected medication to a patient including humans and other animals in accordance with an administration schedule which can be preselected or, in some instances, preprogrammed. Pumps for use in this invention can be worn externally or can be directly implanted into the body of a mammal, including a human, to deliver a specific medication such as insulin to the mammal in controlled doses over an extended period of time. Such pumps are well known and are described, for example, in U.S. Patents 5,957,890, 4,923,375, 4,573,994, and 3,731,681. Medications which should optimally be maintained at a constant level, such as phenobarbital, baclofen, theophylline, and cardiac and blood pressure medications, also can be provided by means of an infusion pump.

### Illustrative embodiments

Illustrative embodiments of the analyte sensor system according to embodiments of the invention are shown in FIGS. 1 and 2. FIG. 1 is a schematic view of an analyte sensor system employing a contact lens 1, a radiation detector 5, such as a fluorophotometer, and



WO 01/13783

PCT/EP00/08285

- 8 -

a radiation source **2**, such as a laser (which preferably is of low power) or light emitting diode, which emits light **3** with a first wavelength which will excite the fluorescent label in competitor moieties contained within the contact lens **1**. In response to the light **3**, competitor moieties which are not bound to receptor moieties will thereby emit light **4** of a second different wavelength (*e.g.*, by fluorescence), which can be detected and measured by a radiation detector **5**. The radiation detector **5** and the radiation source **2** may be embodied together as a hand-held unit, as shown in FIG. 1.

Conveniently, a miniaturized version of the radiation source **2** and the radiation detector **5** can be configured to be built into a pair of eyeglasses. An exemplary embodiment of this is shown in FIGS. 2A and 2B. The analyte sensor system shown in FIGS. 2A and 2B employs an intraocular lens **8**, which comprises a polymer **9** containing receptor moieties and fluorescently labeled competitor moieties. A light-emitting diode **6** is mounted in the frame of a pair of eyeglasses **7**. The light-emitting diode **6** emits light **3** with a first wavelength which will excite the fluorescent label in the competitor moieties. Competitor moieties which are not bound to receptor moieties will thereby emit light **4** of a second different wavelength, which can be detected and measured by a fluorophotometer **5**, which is mounted together with the light-emitting diode **6** in the eyeglasses frame **7**. A telemetry signal **10** is transmitted to an infusion pump **11**, which can provide a regulator moiety, such as insulin, to maintain suitable levels of the analyte in the body. The telemetry signal **10** may be analog or digital and may be transmitted via wire or cable, such as wire **60**, or wirelessly, such as via radio frequency or infrared transmission. Where the telemetry signal **10** is transmitted wirelessly, the analyte sensor system may include antennas **50**, **51**, for such wireless transmission. Antenna **50** may, if desired, be embedded within eyeglass frame **7**. As shown in FIG. 2C, the antennas **50**, **51** may be coupled with a respective wireless transmitter **52** and wireless receiver **53**.

The telemetry signal **10** may include qualitative information as to whether or not the analyte is detected by the radiation detector **5**. For example, where the detected light **4** is at or exceeds a predetermined threshold, the telemetry signal **10** may represent a "detected" state (such as the existence of telemetry signal **10**). Where the detected light **4** is below the threshold, the telemetry signal **10** may represent a "not detected" state (such as the absence of telemetry signal **10**). Alternatively, the telemetry signal **10** may indicate a

WO 01/13783

PCT/EP00/08285

- 9 -

change in analyte concentration. Telemetry signal **10** also may provide a warning signal if the analyte concentration is above or below a preset range.

Optionally, the telemetry signal **10** may include quantitative information as to how much light **4** is detected by the radiation detector **5**. For instance, the telemetry signal **10** may be varied in amplitude and/or frequency responsive to the amount of light **4** detected, where the amplitude and/or frequency represents the amount of light **4**. As another example, the telemetry signal **10** may include digital data representing the amount of detected light **4**.

If the telemetry signal **10** is analog, the telemetry signal **10** may be generated by the detector **5**, which may include a modulator for generation of the telemetry signal **10**. If the telemetry signal **10** is digital, the telemetry signal **10** may be generated by an analog-to-digital ("A/D") converter **70**. Also, the amount of the light **4** detected by the radiation detector **5** may be shown on a display **71** (which may include a display driver), such as a CRT screen or liquid crystal display ("LCD").

All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

### **EXAMPLE 1**

#### *Construction of an intraocular glucose sensor*

A structurally stable polymer of polyethylene glycol hydrogel (PEGH, Shearwater Polymers, Inc.) is used to construct an intraocular glucose sensor. PEGH is immobilized in an intraocular lens (Alcon Laboratories, 6 mm circumference, 1 mm thickness). Chemically immobilized pendant tetramethylrhodamine isothiocyanate concanavalin A (TRITC-ConA, Sigma) is incorporated into the PEGH as the receptor moiety and fluorescein isothiocyanate dextran (FITC-dextran, Sigma) is incorporated as the competitor moiety by polymerization under UV light, as described by Ballerstadt & Schultz, *Anal. Chim. Acta* **345**, 203-12, 1997, and Russell & Pishko, *Anal. Chem.* **71**, 3126-32, 1999. While the FITC-dextran is bound to the TRITC-ConA, the FITC fluorescence is quenched via a fluorescence resonance energy

WO 01/13783

PCT/EP00/08285

- 10 -

transfer. Increased glucose concentration frees the FITC-dextran and results in fluorescence which is proportional to glucose concentration.

FIG. 4 shows the relationship between fluorescence intensity of our fluorescent intraocular lens at three glucose concentrations *in vitro*. A linearly proportional relationship occurs between 0 and 500 mg% at 518 nm, which is the peak of fluorescein fluorescence. The peak at 575 nm is due to the rhodamine in the TRITC-ConA.

## **EXAMPLE 2**

### *Implantation of an intraocular glucose sensor in vivo*

The intraocular lens glucose sensor described in Example 1 is implanted into the anterior chamber of the eye of a living New Zealand rabbit with a blood glucose concentration of 112 mg%. The implant is visible as a bright spot of green fluorescence (518 nm) within the eye. Careful examination with a biomicroscope slit lamp shows no sign of toxicity, rejection, or any reaction 6 months after implantation.

WO 01/13783

PCT/EP00/08285

- 11 -

**CLAIMS**

1. An ophthalmic lens for detecting an analyte in an ocular fluid, comprising:  
a receptor moiety which comprises an analyte/competitor moiety binding site.
2. The ophthalmic lens of claim 1 which further comprises a competitor moiety comprising a detectable label.
3. The ophthalmic lens of claim 1 which is selected from the group consisting of a contact lens, an intraocular lens, a subconjunctival lens, and an intracorneal lens.
4. The ophthalmic lens of claim 1, wherein the analyte is selected from the group consisting of an electrolyte, a metallic element, a polypeptide hormone, a chronically administered medication, an acutely administered medication, a small molecule hormone, a marker of inflammation, a marker of allergy, a lipid, a protein, a marker of infection, and a metabolite.
5. The ophthalmic lens of claim 1, wherein the ocular fluid is selected from the group consisting of tears, aqueous humor, and interstitial fluid.
6. The ophthalmic lens of claim 1, wherein the receptor moiety is covalently bound to the ophthalmic lens.
7. The ophthalmic lens of claim 2 which comprises a polymer meshwork, wherein pores of the polymer meshwork (a) permit the competitor moiety to bind reversibly to the analyte/-competitor moiety binding site and (b) prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens.
8. The ophthalmic lens of claim 2 which comprises:  
a receptor moiety layer;  
a polyelectrolyte layer; and  
a competitor moiety layer
9. The ophthalmic lens of claim 2, wherein the detectable label is a fluorescent label.
10. An ophthalmic lens for detecting glucose in an ocular fluid, comprising:  
a receptor moiety layer, wherein receptor moieties in the receptor moiety layer comprise glucose/competitor moiety binding sites;  
a first and a second polyelectrolyte layer; and  
a competitor moiety layer, wherein competitor moieties in the competitor moiety layer comprise detectable labels.
11. The ophthalmic lens of claim 10, wherein the receptor moiety layer comprises concanavalin A molecules.

WO 01/13783

PCT/EP00/08285

- 12 -

12. The ophthalmic lens of claim 10, wherein the competitor moiety layer comprises fluorescein dextran molecules.
13. An analyte sensor system, comprising:
  - (a) an ophthalmic lens for detecting an analyte in an ocular fluid, comprising:
    - (i) a receptor moiety which comprises an analyte/competitor moiety binding site; and
    - (ii) a competitor moiety comprising a detectable label; and
  - (b) a detector configured to detect the detectable label.
14. The analyte sensor system of claim 13, wherein the detector includes a fluorophotometer.
15. The analyte sensor system of claim 13, further comprising a transmitter coupled to the detector and configured to transmit to a pump a signal indicating whether the detectable label is detected by the detector, wherein the pump is configured to vary a concentration of the analyte in a body fluid or tissue.
16. The analyte sensor system of claim 15, wherein the transmitter is contained in a personal accessory.
17. The analyte sensor system of claim 15, further comprising the pump.
18. The analyte sensor system of claim 15, wherein the transmitter is further configured to transmit the signal to the pump wirelessly.
19. The analyte sensor system of claim 15, wherein the analyte is glucose and the body fluid is blood.
20. The analyte sensor system of claim 19, wherein the receptor moiety is concanavalin A.
21. The analyte sensor system of claim 19, wherein the competitor moiety is fluorescein dextran.
22. The analyte sensor system of claim 19, wherein the pump is an insulin pump.
23. The analyte sensor system of claim 13 wherein the ophthalmic lens is selected from the group consisting of a contact lens, an intraocular lens, a subconjunctival lens, and an intracorneal lens.
24. The analyte sensor system of claim 13, wherein the ophthalmic lens comprises a polymer meshwork, wherein pores of the polymer meshwork (a) permit a competitor moiety to bind reversibly to the analyte/competitor moiety binding site and (b) prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens.
25. The analyte sensor system of claim 13, wherein the ophthalmic lens comprises:  
a receptor moiety layer;

WO 01/13783

PCT/EP00/08285

- 13 -

a polyelectrolyte layer; and  
a competitor moiety layer.

26. The ophthalmic lens of claim 13, wherein the ocular fluid is selected from the group consisting of tears, aqueous humor, and interstitial fluid.

27. A method for measuring the concentration of an analyte in an ocular fluid, comprising the steps of:

(a) contacting the ocular fluid with an ophthalmic lens, wherein the ophthalmic lens comprises:

(i) a receptor moiety which comprises an analyte/competitor moiety binding site; and  
(ii) a competitor moiety which comprises a detectable label; and

(b) detecting the detectable label, wherein the amount of detectable label detected indicates the concentration of the analyte in the ocular fluid.

28. The method of claim 27, wherein the ophthalmic lens is selected from the group consisting of a contact lens, an intraocular lens, a subconjunctival lens, and an intracorneal lens.

29. The method of claim 27, wherein the analyte is selected from the group consisting of electrolytes and small molecules, metallic elements, polypeptide hormones, chronically administered medications, acutely administered medications, small molecule hormones, markers of inflammation, markers of allergy, lipids, proteins, markers of infection, and metabolites.

30. The method of claim 27, wherein the ocular fluid is selected from the group consisting of tears, aqueous humor, and interstitial fluid.

31. The method of claim 27, wherein the receptor moiety is covalently bound to the ophthalmic lens.

32. The method of claim 27, wherein the ophthalmic lens comprises a polymer meshwork, wherein pores in the polymer meshwork (a) permit a competitor moiety to bind reversibly to the analyte/competitor moiety binding site and (b) prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens.

33. The method of claim 27, wherein the ophthalmic lens comprises:

a receptor moiety layer;  
a polyelectrolyte layer; and  
a competitor moiety layer.

34. The method of claim 27, wherein the detectable label is a fluorescent label.

WO 01/13783

PCT/EP00/08285

- 14 -

35. The method of claim 27, wherein the ocular fluid is selected from the group consisting of tears, aqueous humor, and interstitial fluid.
36. A method for varying the concentration of an analyte in an ocular fluid, comprising the steps of:
- (a) contacting the ocular fluid with an ophthalmic lens, wherein the ophthalmic lens comprises:
    - (i) a competitor moiety which comprises a detectable label; and
    - (ii) a receptor moiety which comprises an analyte/competitor moiety binding site;
  - (b) detecting the detectable label, wherein the amount of detectable label detected indicates the concentration of the analyte in a body tissue or fluid;
  - (c) transmitting a signal indicating the concentration of the analyte in the ocular fluid to a pump configured to vary the concentration of the analyte in the body tissue or fluid; and
  - (d) providing a regulator moiety via the pump to the body tissue or fluid, whereby the concentration of the analyte in the body tissue or fluid is varied.
37. The method of claim 36 wherein the detectable label is a fluorescent label.
38. The method of claim 37 wherein the detectable label is detected by a fluorophotometer.
39. The method of claim 38 wherein the fluorophotometer is contained in a personal accessory.
40. The method of claim 36 wherein the ocular fluid is selected from the group consisting of tears, aqueous humor, and interstitial fluid.
41. The method of claim 36 wherein the analyte is glucose.
42. The method of claim 41 wherein the receptor moiety is concanavalin A.
43. The method of claim 41 wherein the competitor moiety is fluorescein dextran.
44. The method of claim 41 wherein the regulator moiety is insulin.
45. The method of claim 36 wherein the ophthalmic lens is selected from the group consisting of a contact lens, an intraocular lens, a subconjunctival lens, and an intracorneal lens.
46. The method of claim 36, wherein the receptor moiety is covalently bound to the ophthalmic lens.
47. The method of claim 36, wherein the ophthalmic lens comprises a polymer meshwork, wherein pores of the polymer meshwork (a) permit a competitor moiety to bind reversibly to the analyte/competitor moiety binding site and (b) prevent the receptor moiety and the competitor moiety from diffusing out of the ophthalmic lens.

WO 01/13783

PCT/EP00/08285

- 15 -

48. The method of claim 36, wherein the ophthalmic lens comprises:  
a receptor moiety layer;  
a polyelectrolyte layer; and  
a competitor moiety layer.
49. A kit for detecting an analyte in an ocular fluid, comprising:  
an ophthalmic lens comprising a receptor moiety which comprises an analyte/competitor moiety binding site; and  
instructions for using the ophthalmic lens to detect the analyte.
50. The kit of claim 49, further comprising a competitor moiety comprising a detectable label.
51. The kit of claim 49, further comprising a detector configured to detect the detectable label.
52. A kit for detecting glucose in an ocular fluid, comprising:  
a contact lens comprising concanavalin A and fluorescein dextran; and  
instructions for using the contact lens to detect glucose in the ocular fluid.
53. The kit of claim 52, further comprising a detector for detecting fluorescence of fluorescein dextran which is not bound to the concanavalin A.



WO 01/13783

PCT/EP00/08285

FIG. 1




FIG. 3A




FIG. 3B






FIG. 3C



WO 01/13783


PCT/EP00/08285





WO 01/13783

PCT/EP00/08285



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/08285

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61B5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, INSPEC, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 19188 A (ANTWERP WILLIAM PETER VAN ;MINIMED INC (US); MASTROTOTARO JOHN JOS) 29 May 1997 (1997-05-29) page 4, line 18 -page 5, line 5 page 6, line 15 -page 26, line 5; tables 1,2	1-14,25
Y	WO 93 01745 A (GEORGIA TECH RES INST) 4 February 1993 (1993-02-04) page 4, line 22 -page 5, line 24 page 6, line 25 -page 8, line 12; table 1 --- -/--	1-14,25

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

11 January 2001

Date of mailing of the international search report

22/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer:

Weihs, J

## INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/EP 00/08285

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KOMIVES C ET AL: "IMPROVEMENT OF OPTICAL FIBER BASED BIOSENSORS" PROCEEDINGS OF THE ANNUAL CONFERENCE OF THE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY,US,NEW YORK, IEEE, vol. CONF. 12, 1 November 1990 (1990-11-01), pages 478-479, XP000236249	11,12
A	* see whole document *	20,21, 52,53
P,A	WO 00 13580 A (ROE JEFFREY N ;AMIRAL MEDICAL (US); DOUGLAS JOEL S (US); YUM SU I) 16 March 2000 (2000-03-16) page 7, line 15 -page 9, line 16; tables 1-3	15,17,19
P,X	WO 99 51142 A (GEN HOSPITAL CORP ;KOLLIAS NIKIFOROS (US); TIAN WEI DONG (US); FRE) 14 October 1999 (1999-10-14)	1,2,5,7, 9,10,13, 14,25, 26,49-51
A	page 2, line 10 -page 4, line 7  page 5, line 12 -page 8, line 28; tables 1,2	3,6,23, 24

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/08285

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9719188 A	29-05-1997	AU 1058297 A	11-06-1997
		CA 2235738 A	29-05-1997
		EP 0862648 A	09-09-1998
		JP 2000500656 T	25-01-2000
		US 6011984 A	04-01-2000
WO 9301745 A	04-02-1993	US 5203328 A	20-04-1993
		AT 158704 T	15-10-1997
		AU 661026 B	13-07-1995
		AU 2373392 A	23-02-1993
		CA 2113268 A,C	04-02-1993
		DE 69222535 D	06-11-1997
		DE 69222535 T	26-03-1998
		EP 0597932 A	25-05-1994
		ES 2110007 T	01-02-1998
		JP 7500030 T	05-01-1995
		US 5582168 A	10-12-1996
WO 0013580 A	16-03-2000	AU 6142799 A	27-03-2000
WO 9951142 A	14-10-1999	AU 3385999 A	25-10-1999